Acquired by EIP Pharma, Inc. in Oct 2023
DFFN - Diffusion Pharmaceuticals Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Charlottesville,
United States
Type: Equity
DFFN price evolution
DFFN
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15 | $14.65 | $10.11 | $6.59 |
| Short term investments | $2.99 | $12.41 | $19.27 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $15.69 | $18.4 | $22.64 | $26.32 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | $2.99 | $12.41 | $19.27 | |
| Total assets | $15.69 | $18.4 | $22.64 | $26.32 |
| Current liabilities | ||||
| Accounts payable | $0.93 | $0.97 | $1.13 | $0.81 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.46 | $2.13 | $2.42 | $2.27 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1.46 | $2.13 | $2.42 | $2.27 |
| Shareholders' equity | ||||
| Retained earnings | -$151.8 | -$149.69 | -$145.6 | -$141.52 |
| Other shareholder equity | -$0 | -$0.04 | -$0.09 | |
| Total shareholder equity | $14.23 | $16.28 | $20.22 | $24.05 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10.11 | $37.31 | $18.52 | $14.18 |
| Short term investments | $12.41 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $22.64 | $37.82 | $18.78 | $14.65 |
| Long term investments | ||||
| Property, plant & equipment | $0.3 | $0.5 | ||
| Goodwill & intangible assets | $8.64 | $8.64 | ||
| Total noncurrent assets | $0.02 | $8.95 | $9.46 | |
| Total investments | $12.41 | |||
| Total assets | $22.64 | $37.84 | $27.73 | $24.11 |
| Current liabilities | ||||
| Accounts payable | $1.13 | $0.95 | $0.55 | $1.25 |
| Deferred revenue | ||||
| Short long term debt | $0.11 | $0.11 | ||
| Total current liabilities | $2.42 | $2.93 | $2.44 | $1.72 |
| Long term debt | $0.04 | $0.14 | ||
| Total noncurrent liabilities | $0.48 | $2.25 | ||
| Total debt | $0.15 | $0.25 | ||
| Total liabilities | $2.42 | $2.93 | $2.92 | $3.98 |
| Shareholders' equity | ||||
| Retained earnings | -$145.6 | -$130.01 | -$105.91 | -$91.72 |
| Other shareholder equity | -$0.04 | $0 | ||
| Total shareholder equity | $20.22 | $34.91 | $24.81 | $20.13 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.07 | $1.31 | $1.9 | $0.8 |
| Selling, general & administrative | $2.22 | $2.96 | $2.34 | $2.12 |
| Total operating expenses | $2.29 | $4.27 | $4.25 | $2.92 |
| Operating income | -$2.29 | -$4.27 | -$4.25 | -$2.92 |
| Income from continuing operations | ||||
| EBIT | -$2.11 | -$4.09 | -$4.08 | -$2.8 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$2.11 | -$4.09 | -$4.08 | -$2.8 |
| Income (for common shares) | -$2.11 | -$4.09 | -$4.08 | -$2.8 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.24 | $8.5 | $9.43 | $6.62 |
| Selling, general & administrative | $8.74 | $7.45 | $6.44 | $4.83 |
| Total operating expenses | $15.97 | $24.68 | $15.97 | $11.55 |
| Operating income | -$15.97 | -$24.68 | -$15.97 | -$11.55 |
| Income from continuing operations | ||||
| EBIT | -$15.59 | -$24.54 | -$15.86 | -$11.55 |
| Income tax expense | -$0.44 | -$1.68 | $0.33 | |
| Interest expense | -$0.09 | |||
| Net income | ||||
| Net income | -$15.59 | -$24.1 | -$14.19 | -$11.8 |
| Income (for common shares) | -$15.59 | -$24.1 | -$16.14 | -$11.8 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$2.11 | -$4.09 | -$4.08 | -$2.8 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.06 | $0.12 | $0.19 | $0.18 |
| Total cash flows from operations | -$2.65 | -$4.97 | -$3.47 | -$2.76 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $3 | $9.5 | $7 | $3.38 |
| Total cash flows from investing | $3 | $9.5 | $7 | $3.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.35 | $4.53 | $3.53 | $0.62 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$15.59 | -$24.1 | -$14.19 | -$11.8 |
| Operating activities | ||||
| Depreciation | $0.09 | $0.1 | $0.1 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.93 | $0.9 | $0.74 | $0.52 |
| Total cash flows from operations | -$14.97 | -$14.5 | -$13.55 | -$9.86 |
| Investing activities | ||||
| Capital expenditures | $0 | |||
| Investments | -$12.24 | |||
| Total cash flows from investing | -$12.24 | $0 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $33.3 | $18.87 | $16.21 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.01 | $33.3 | $17.89 | $16.04 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$27.2 | $18.8 | $4.34 | $6.19 |
News
|
Fetterman's struggles with language highlight the challenges after a stroke – a vascular neurologist...
The Conversation via Yahoo News
28 Oct 2022
|
|
62 Biggest Movers From Yesterday
Benzinga
28 Apr 2022
|
|
38 Stocks Moving In Tuesday's Mid-Day Session
Benzinga
19 Apr 2022
|
|
68 Biggest Movers From Yesterday
Benzinga
19 Apr 2022
|
|
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.11% By Investing.com
Investing.com
18 Apr 2022
|
|
Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow
Benzinga via Yahoo Finance
18 Apr 2022
|
|
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.11%
Investing.com
18 Apr 2022
|
|
10 Biotech Penny Stocks with Growth Catalysts
Insider Monkey via Yahoo Finance
6 Apr 2022
|
|
63 Biggest Movers From Yesterday
Benzinga
25 Mar 2022
|
|
58 Biggest Movers From Yesterday
Benzinga
24 Mar 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.04M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$13.08M |
| EBIT | -$13.08M |
| Net Income | -$13.08M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 6.97 |
| Cash/Share | 7.35 |
| EPS | -$6.41 |
|---|---|
| ROA | -62.99% |
| ROE | -69.97% |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | 1.03 |
| Current ratio | 10.71 |
| Quick ratio | 10.71 |